Home

Imperative Care Presents Positive Real-World Data from Ischemic Stroke Patients Treated with ADAPT 2.0 Using the Zoom Stroke System

via Business Wire

Late-Breaking Data Presented at Society of Vascular and Interventional Neurology Annual Meeting Demonstrated Excellent Reperfusion and Rapid Procedure Times with the Zoom Stroke System Using Large-Bore Intracranial Access, Asymmetric Aspiration, and Continuous Dual Aspiration

Imperative Care, Inc. today announced the presentation of late-breaking, real-world data from a multi-center review of ischemic stroke patients treated with ADAPT 2.0, a next-generation approach to A Direct Aspiration First Pass Technique (ADAPT). ADAPT 2.0 combines 0.088” intracranial access, asymmetric aspiration, and the continuous dual aspiration technique (CDAT) to provide fast and effective clot removal. Imperative Care’s Zoom Stroke System is the only mechanical thrombectomy system capable of performing a procedure using ADAPT 2.0. The findings were presented at the Society of Vascular and Interventional Neurology (SVIN) 2025 Annual Meeting in Orlando, Fla.

ADAPT 2.0 represents the evolution of the original ADAPT technique, initially studied and published in 20141. The original ADAPT approach transformed stroke thrombectomy by demonstrating the clinical value of direct aspiration as a frontline treatment method, achieving excellent clinical and angiographic outcomes with efficiency and ease of use2. ADAPT 2.0 brings together the most advanced techniques and technologies into a streamlined approach for achieving faster, easier and more effective stroke cases. The ADAPT 2.0 approach is intended to bring the 0.088” catheter closer to the clot, improve clot ingestion through asymmetric aspiration, and reduce the risk of losing clot by applying continuous dual aspiration. We believe this approach offers physicians greater control and consistency during thrombectomy procedures.

Data from the multi-center review of 124 consecutive ischemic stroke patients treated with ADAPT 2.0 using the Zoom Stroke System between April 2025 and September 2025 were presented by Max Mokin, M.D., Ph.D., University of South Florida. The most frequent occlusion site reported in patients was the M1 segment of the middle cerebral artery (48%, 59/124), followed by the M2 segment (24%, 30/124). The review of clinically documented data observed:

  • A 97% rate of final modified thrombolysis in cerebral infarction (mTICI) ≥ 2b (120/124) and an 80% rate of final mTICI ≥ 2c (99/124);
  • A median procedure time of 17 minutes, with a median of one pass per procedure;
  • A 98% rate of full clot ingestion and capture in one or both Zoom PODs (111/113); and
  • Outer Zoom 88 POD captured clot in 35% of cases (40/113), which may have otherwise been lost.

“We are thrilled to see the procedural benefits of ADAPT 2.0 – a potential next frontier in stroke care – represented so clearly in the results of this study,” said Emir Deljkich, Senior Vice President of Clinical Affairs. “The combined power of 0.088” intracranial access, asymmetric aspiration, and CDAT using the Zoom Stroke System, allows physicians to not only streamline their procedures by using fewer devices, but gain greater control over the clot. This translates to faster and simpler procedures, as evidenced by a 17-minute median procedure time reported in this real-world dataset. Recent clinical data demonstrated that a faster puncture-to-reperfusion time led to a higher rate of functional independence – pointing to the critical importance of treatment time for stroke patients3. We look forward to gathering additional prospective evidence to further validate the clinical performance of ADAPT 2.0 in stroke thrombectomy.”

Dr. Mokin added, “In addition to the 17-minute median procedure time and the minimal number of passes per procedure, we saw a 98% rate of full clot ingestion in this cohort, meaning the entire clot was successfully captured in one or both Zoom PODs. Clot was observed in the Zoom 88 POD in 35% of all cases, which may have otherwise been lost without continuous dual aspiration on the inner and outer catheters. This underscores a key potential benefit of ADAPT 2.0, providing physicians with greater control and confidence during stroke procedures by reducing the risk of clot loss and offering immediate visual feedback of clot capture. I look forward to future larger studies to further elucidate the clinical benefits of CDAT and ADAPT 2.0 for stroke patients.”

About the Zoom Products

The Zoom System is designed to be a complete stroke system from access through reperfusion for fast and effective clot removal in patients presenting with acute ischemic stroke. Imperative Care’s Zoom System consists of the Zoom 35, 45, 55, 71 and 7X Catheters, Zoom 88 Large Distal Platform, Zoom 88 Support, Zoom POD and Zoom Aspiration/Zoom POD tubing, Zoom Canister and DuoPort Canister.

All Zoom Catheters are designed with an asymmetric TRX™ Tip, which provides 15% greater clot engagement area at the tip of the catheter, relative to a traditional flat-tip catheter,4 and are constructed to enable smooth tracking through challenging vasculature. For complete product information, including indications, contraindications, warnings, precautions and adverse events, visit: https://bit.ly/3yWkfEJ.

About Imperative Care, Inc.

Imperative Care is a commercial-stage medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, a serious medical condition caused by blood clot formation inside veins and arteries. Imperative Care was founded with the mission of bringing lifesaving treatments to patients suffering from ischemic stroke and other devastating vascular diseases caused by blood clot formation. The company’s commercially available product portfolio includes the Zoom Stroke System, the Symphony Thrombectomy System and the Prodigy Thrombectomy System. In addition to its commercial products, the company is developing the Telos robotic platform*, an endovascular robotic system designed to bring greater precision and standardization to procedures and expand access to lifesaving treatment. Imperative Care is based in Campbell, Calif. https://imperativecare.com.

  1. Turk AS, et al. Initial clinical experience with the ADAPT technique: a direct aspiration first pass technique for stroke thrombectomy. J Neurointerv Surg. 2014;6(3):231-237
  2. Turk AS, Frei D, Fiorella D, et al. ADAPT FAST study: a direct aspiration first pass technique for acute stroke thrombectomy. J Neurointerv Surg. 2014;6:260-264.
  3. Saad, Hassan, et al. “Procedure Duration Predicts Outcomes More Than Prehospital Delay in Endovascular Stroke Treatment.” Journal of NeuroInterventional Surgery, Sept. 19, 2025, doi:10.1136/jnis-2025-023906.
  4. Vargas J, Blalock J, Venkatraman A, et al. Efficacy of beveled tip aspiration catheter in mechanical thrombectomy for acute ischemic stroke. J Neurointerv Surg. 2021;13:823-826.

*Currently in development. Not approved for use or available for sale.

Dr. Max Mokin is a paid consultant for Imperative Care.

Contacts